18.3: Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.

Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism of action. They are divided between short-acting therapy (rescue) and long-acting therapy (maintenance).

Drugs for rescue therapy include short-acting β2-adrenoceptor agonists that engage β2-adrenergic receptors, relaxing the bronchial muscles, facilitating smoother airflow, and providing quick relief during acute bronchoconstriction. While methylxanthines, such as theophylline, are typically not used in rescue therapy, they act as bronchodilators by inhibiting phosphodiesterase enzymes (PDEs), particularly PDE-4, in airway smooth muscle. This inhibition prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to increased intracellular cAMP levels. Elevated cAMP activates protein kinase A (PKA), which reduces muscle contraction signals, resulting in relaxed bronchial smooth muscles and improved airflow, providing significant relief for individuals with respiratory distress. Additionally, muscarinic receptor antagonists block acetylcholine receptors from binding to M3 receptors in these bronchial muscles, enabling them to relax and fostering improved breathing.

Management of long-acting therapy may include long-acting β2-adrenoceptor agonists. Cysteinyl leukotriene receptor antagonists are anti-inflammatory drugs that specifically target and reduce bronchoconstriction.

Additional anti-inflammatory drugs are critical in controlling inflammation in the lower respiratory tract. Glucocorticoids either directly suppress inflammatory genes or activate anti-inflammatory counterparts. As a result, they curb the cascade of inflammation that can severely damage airways. Mast cell stabilizers prevent the release of inflammatory mediators from mast cells and are commonly used as antiasthmatic drugs to reduce inflammation and help manage asthma symptoms. They inhibit the influx of calcium ions into mast cells, effectively blocking the unnecessary release of these agents that contribute to ongoing inflammation.

Finally, immunomodulators, including IgE and interleukin inhibitors, strategically suppress the elements that trigger allergic reactions and protect the respiratory system from the collateral damage of chronic inflammation.

The management of asthma and COPD requires careful evaluation of causes, symptoms, and treatments. Clinicians must monitor the effectiveness of these treatments and make necessary adjustments to maximize the effectiveness of care.

Common lower respiratory disorders, such as asthma and chronic obstructive pulmonary disease, are managed with bronchodilators and anti-inflammatory drugs.

Bronchodilators, such as methylxanthines, β2-adrenoceptor agonists, muscarinic receptor antagonists, and cysteinyl leukotriene receptor antagonists, relax airway muscles for easier breathing.

Methylxanthines stimulate the central nervous system to induce bronchodilation, while β2-adrenoceptor agonists activate β2-adrenergic receptors and muscarinic receptor antagonists block acetylcholine binding to muscarinic receptors in the bronchial muscles.

Anti-inflammatory drugs such as glucocorticoids, mast cell stabilizers, and immunomodulators reduce or prevent inflammation.

Glucocorticoids directly suppress inflammatory genes or activate anti-inflammatory genes, while mast cell stabilizers inhibit calcium ion entry into mast cells, preventing the release of inflammatory mediators.

Conversely, immunomodulators target specific immune responses to allergic inflammation.